XERIS BIOPHARMA HOLDINGS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-02
- XERIS BIOPHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $20.04M.
- XERIS BIOPHARMA HOLDINGS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $20.04M derived: sum of 3 quarters · filed 2026-03-02 | $20.04M 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | $20.04M derived: sum of 2 quarters · filed 2024-11-08 | $20.04M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $20.04M 10-Q · filed 2024-08-08 | $20.04M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $0.00 derived: sum of 2 quarters · filed 2024-03-06 | $0.00 derived: sum of 3 quarters · filed 2024-03-06 | $0.00 10-K · filed 2024-03-06 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |